A Safety Study of ARRY-371797 in Healthy Subjects
Launched by ARRAY BIOPHARMA, NOW A WHOLLY OWNED SUBSIDIARY OF PFIZER · Nov 11, 2008
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Key Inclusion Criteria:
- • Healthy male or female between the ages of 18 and 60 years.
- • Females must be of nonchildbearing potential.
- • Body weight \> 50 kg (110 lbs) and \< 113 kg (250 lbs).
- • Additional criteria exist.
- Key Exclusion Criteria:
- • A positive test for drugs or alcohol.
- • Use of prescription or nonprescription drugs, herbal or dietary supplements, vitamins, or grapefruit juice within 14 days prior to first dose of study drug.
- • Additional criteria exist.
About Array Biopharma, Now A Wholly Owned Subsidiary Of Pfizer
Array Biopharma, now a wholly owned subsidiary of Pfizer, is a biopharmaceutical company dedicated to the discovery and development of innovative targeted therapies for the treatment of cancer. With a focus on precision medicine, Array leverages its extensive expertise in drug development and molecular biology to advance a robust pipeline of potential therapeutics. The company is committed to improving patient outcomes through rigorous clinical research and collaboration, aiming to deliver breakthrough treatments that address unmet medical needs in oncology.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Austin, Texas, United States
Patients applied
Trial Officials
Pfizer CT.gov Call Center
Study Director
Pfizer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials